$GILD · Gilead Sciences

Thesis

GILD prints a GAAP loss on the acquired-IPR&D writedown but adjusted EPS should decouple within 30 minutes. Biktarvy holds, oncology (Trodelvy) is the swing factor, and Leerink's recent downgrade thins out the sell-side. Setup mirrors MRK 8/4 BMO which printed +0.75% on a similar charge structure.

What would flip it

FY26 adj-EPS guide cut beyond the pure IPR&D headline flips this to DOWN -2 to -3%.

The market's narrative

Biktarvy franchise durability + Trodelvy oncology ramp are the offsetting story to the announced-M&A / IPR&D one-time charge headline that will look ugly on GAAP scoreboard.

Where the Street may be wrong

• Adjusted-EPS ex-IPR&D-charge should print $2.00-2.10, decoupling from the -$7.25 GAAP consensus — tape reads the adjusted number after 30 minutes but headline algos may fade on GAAP loss initially
• CEO O'Day Aug 3 Form-4 sale of 55K shares at $130 was the day BEFORE print — typical pre-blackout window closing, not directional signal

Peer read: MRK 8/4 BMO printed +0.75% with $2.31/sh Terns IPR&D charge headline; Adj-EPS beat drove the mild UP. GILD in analogous setup — template = defensive-pharma-with-one-time-M&A-charge = mild UP +0.5 to +1.5%.

Reasoning

• Fundamentals: Biktarvy ~$3.4B (+3% YoY), Descovy ~$0.55B, oncology (Trodelvy + Yescarta) growing MSD/HSD, liver franchise stable. Adjusted EPS beat likely, GAAP loss due to IPR&D charge.
• Positioning: spot 16% below avg PT $159, RSI 55.9 mid-range — not stretched either direction.
• Insider: CEO Aug 3 sale looks bearish at face value but timing = last day of open trading window before earnings blackout, so treat as neutral signal not directional.
• Sentiment: Leerink Jul 21 downgrade to Market Perform is the sell-side capitulation — skeptical positioning is a mild positive (VZ template).
• Applied lesson: MRK 8/4 template validated — defensive pharma with one-time M&A/IPR&D charge = mild UP as adj-EPS decouples from GAAP headline.